Beam Therapeutics Inc. quarterly report, Q1 FY2022

Beam Therapeutics Inc. — Form 10-Q Summary

Reporting period: Three months ended March 31, 2022; filed May 9, 2022. Beam is an early-stage biotechnology company developing precision genetic medicines based primarily on base-editing technology. Its programs remain preclinical or in early clinical development, and it has generated no product sales.

Key financial metrics

Metric	Q1 2022	Q1 2021	Change
License and collaboration revenue	$8.4 million	$6 thousand	+$8.4 million
Research and development expense	$65.4 million	$190.1 million	-$124.7 million
General and administrative expense	$19.2 million	$10.3 million	+$9.0 million
Total operating expenses	$84.7 million	$200.4 million	-$115.7 million
Loss from operations	$76.2 million	$200.4 million	Improved by $124.1 million
Net loss	$69.2 million	$201.6 million	Improved by $132.3 million
Net loss per share	$1.01	$3.35	Improved
Net cash provided by operating activities	$218.5 million	$(38.6) million	+$257.1 million

The quarter remained loss-making, with no meaningful operating profitability or product revenue. The operating loss was approximately nine times reported revenue, although the comparison is distorted by collaboration revenue recognized over time.

Balance sheet, cash, debt, and liquidity

Cash and cash equivalents were $296.8 million at March 31, 2022, compared with $560.0 million at December 31, 2021.
Marketable securities increased to $925.8 million from $405.7 million. Cash, cash equivalents, and marketable securities totaled approximately $1.2 billion.
Total assets were $1.45 billion; total liabilities were $624.3 million; stockholders’ equity was $829.1 million.
Debt was limited: equipment financing liabilities totaled $4.7 million, while lease liabilities totaled approximately $145.4 million. The filing does not identify material traditional funded debt.
Operating cash flow benefited primarily from collection of Pfizer’s $300.0 million upfront payment. Excluding that working-capital benefit, operating cash flow remained negative.
Investing cash outflow was $537.3 million, principally reflecting $530.1 million of net purchases of marketable securities and $7.3 million of property and equipment purchases.
Financing cash inflow was $55.7 million, primarily from $54.0 million of common-stock issuance, plus employee stock-plan and option proceeds.
Management expects cash, cash equivalents, and marketable securities at March 31, 2022 to fund current and planned operations for at least the next 12 months, but states that additional financing will be required to support continuing operations and growth.

Material changes versus Q1 2021

Revenue increased substantially because Beam recognized $6.3 million under its Pfizer collaboration and $2.1 million under its Apellis collaboration; total revenue was $8.4 million.
Research and development expense fell $124.7 million because Q1 2021 included a $155.0 million write-off of in-process research and development acquired from Guide. Excluding that unusual charge, underlying R&D spending increased, driven by personnel, facilities, stock-based compensation, laboratory supplies, outsourced services, and IND-enabling work.
R&D personnel increased from 182 to 321 employees, and general and administrative personnel increased from 34 to 73 employees.
General and administrative expense rose $9.0 million, primarily due to higher personnel and stock-based compensation costs.
Other income included a $13.6 million gain from the reduced fair value of Harvard and Broad success-payment liabilities. This was partly offset by a $7.7 million loss from the decline in the value of Beam’s Verve investment.
Common shares outstanding increased to approximately 69.8 million at March 31, 2022, from approximately 68.4 million at December 31, 2021, reflecting equity issuance and employee-related activity.

Guidance, outlook, commentary, and unusual items

Beam expects to initiate the BEACON-101 Phase 1/2 trial for BEAM-101 in sickle cell disease and enroll the first subject in the second half of 2022.
Management expects to submit INDs for BEAM-102 in sickle cell disease and BEAM-201 in relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoma during the second half of 2022.
Beam plans to begin IND-enabling studies for BEAM-301, nominate another liver-targeted development candidate, and nominate an additional CAR-T development candidate during 2022.
The company expects its 100,000-square-foot cGMP manufacturing facility in North Carolina to be operational in the first quarter of 2023. The facility has an initial estimated $69.0 million of undiscounted minimum lease payments not included in the existing lease-payment table.
The Pfizer collaboration provides a $300.0 million upfront payment, potential milestone consideration of up to $1.35 billion, and royalties. At March 31, 2022, $95.6 million of related deferred revenue was current and $198.1 million was long-term.
Apellis provides potential total upfront and near-term payments of $75.0 million, including a $25.0 million first-anniversary payment due June 30, 2022, subject to the agreement’s terms.
Guide acquisition consideration includes potential additional payments of up to $100.0 million for technology milestones and $220.0 million for product milestones, payable in common stock. The related contingent consideration liability was $30.9 million at March 31, 2022.
Harvard and Broad success-payment liabilities totaled $28.6 million at quarter-end. Beam may owe up to an additional $90.0 million to each institution, depending on applicable valuation conditions.
COVID-19 did not significantly affect Q1 2022 results, but management continues to identify potential supply-chain, facility, workforce, and clinical-development disruption risks.

Principal risks and contingencies

Beam expects continuing operating losses and negative operating cash flows and has no committed external source of capital. Additional equity, debt, collaboration, or licensing financing may be unavailable or dilutive.
All programs require substantial preclinical, clinical, manufacturing, and regulatory investment. Product candidates may fail to demonstrate safety or efficacy or may never receive approval.
The company’s intellectual-property position is exposed to patent-priority, inventorship, interference, opposition, validity, enforceability, and infringement disputes involving CRISPR and gene-editing technologies.
A February 2022 PTAB decision favored the Boston Licensing Parties over the University of California in one interference proceeding, but the decision is being appealed. Other interference proceedings involving Toolgen and Sigma-Aldrich remain unresolved.
Success-payment, sublicense, milestone, lease, manufacturing, and contingent consideration obligations could create significant future cash or equity requirements.
Manufacturing scale-up, clinical supply, delivery technology, off-target editing, long-term safety, competition, employee retention, and regulatory approval remain material execution risks.

Investor verification checklist

Verify the sustainability of collaboration revenue and the timing of deferred-revenue recognition, particularly under the Pfizer and Apellis agreements.
Reconcile operating cash flow for the $300.0 million Pfizer receivable collection and assess the company’s recurring cash burn excluding that one-time working-capital benefit.
Track progress toward the BEACON-101, BEAM-102, BEAM-201, and BEAM-301 regulatory and clinical milestones.
Monitor construction, cost, and operational-readiness risks for the North Carolina manufacturing facility.
Review future dilution from the ATM program, stock compensation, Guide milestone shares, and potential Harvard and Broad settlements.
Follow the CRISPR-related interference, patent, and licensing proceedings and their potential effect on commercialization rights.
Assess whether the approximately $1.2 billion investment portfolio remains sufficient given rising R&D, clinical, manufacturing, and facility expenditures.